Nafazatrom

A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis. (NCI Thesaurus)

YOU MAY ALSO LIKE

Nafarelin Acetate

This GONADORELIN analog has been used in the treatment of central precocious puberty and endometriosis.

NAF1 wt Allele

Human NAF1 wild-type allele is located in the vicinity of 4q32.2 and is approximately 57 kb in length. This allele, which encodes…

NAF1 Gene

This gene plays a role in the assembly of ribosomes and other riboproteins.

NAE1 wt Allele

Human NAE1 wild-type allele is located in the vicinity of 16q22 and is approximately 28 kb in length. This allele, which encodes…

NAE1 Gene

This gene plays a role in the modulation of protein neddylation.

NAE Inhibitor MLN4924

A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. NAE inhibitor MLN4924 binds to and inhibits NAE, which…